Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 105-112

  Rezvani, Andrew R ^a   Storer, Barry E ^b,c   Guthrie, Katherine A ^b   Schoch, H Gary ^b   Maloney, David G ^b,d   Sandmaier, Brenda M ^b,d   Storb, Rainer ^b,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Engraftment; Graft versus host disease; Nonrelapse mortality; Older allogeneic hematopoietic cell donor

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOCRIT; HLA MATCHING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; SIBLING; THROMBOCYTE; UNRELATED DONORS; ACUTE DISEASE; AGED; ALLOTRANSPLANTATION; CHRONIC DISEASE; DONOR; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; AGED; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84927161392     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.021     Document Type: Article

References (31)

1. Deeg H.J., Sandmaier B.M. Who is fit for allogeneic transplantation?. Blood 2010, 116:4762-4770.
2. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
3. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
4. Xhaard A., Porcher R., Chien J.W., et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008, 22:2062-2069.
5. Parimon T., Madtes D.K., Au D.H., et al. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med 2005, 172:384-390.
6. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011, 306:1874-1883.
7. Mauch P., Botnick L.E., Hannon E.C., et al. Decline in bone marrow proliferative capacity as a function of age. Blood 1982, 60:245-252.
8. Cho R.H., Sieburg H.B., Muller-Sieburg C.E. Anew mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood 2008, 111:5553-5561.
9. Dykstra B., de Haan G. Hematopoietic stem cell aging and self-renewal (Review). Cell Tissue Res 2008, 331:91-101.
10. Glauche I., Thielecke L., Roeder I. Cellular aging leads to functional heterogeneity of hematopoietic stem cells: a modeling perspective. Aging Cell 2011, 10:457-465.
11. Meng A., Wang Y., Van Zant G., Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res 2003, 63:5414-5419.
12. Harrison D.E., Astle C.M. Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure. JExp Med 1982, 156:1767-1779.
13. Zaucha J.M., Yu C., Mathioudakis G., et al. Hematopoietic responses to stress conditions in young dogs compared with elderly dogs. Blood 2001, 98:322-327.
14. Geiger H., de Haan G., Florian M.C. The ageing haematopoietic stem cell compartment (Review). Nat Rev Immunol 2013, 13:376-389.
15. Rossi D.J., Jamieson C.H., Weissman I.L. Stems cells and the pathways to aging and cancer (Review). Cell 2008, 132:681-696.
16. Flach J., Bakker S.T., Mohrin M., et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature 2014, 512:198-202.
17. de Haan G., Nijhof W., Van Zant G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood 1997, 89:1543-1550.
18. Storek J., Joseph A., Espino G., et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation (Plenary Paper). Blood 2001, 98:3505-3512.
19. Mathioudakis G., Storb R., McSweeney P.A., et al. Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients (Brief Report). Blood 2000, 96:3991-3994.
20. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
21. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
22. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003, 102:2021-2030.
23. Inamoto Y., Martin P.J., Storer B.E., et al. Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. Haematologica 2014, 99:385-391.
24. Flowers M.E.D., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
25. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. JClin Oncol 2013, 31:1530-1538.
26. Wiseman D.H. Donor cell leukemia: a review. Biol Blood Marrow Transplant 2011, 17:771-789.
27. Kollman C., Howe C.W.S., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
28. Robin M., Porcher R., Ades L., et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. Bone Marrow Transplant 2013, 48:1296-1301.
29. Peffault de Latour R., Brunstein C.G., Porcher R., et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013, 19:1355-1360.
30. Servais S., Porcher R., Xhaard A., et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica 2014, 99:519-526.
31. Alousi A.M., Le-Rademacher J., Saliba R.M., et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. Blood 2013, 121:2567-2573.